ArticleScientific reports2025
Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A tool to assess the internal validity of toxicokinetic studies.Archives of toxicology · 2026Article
- Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity.Molecular biology reports · 2026Review
- In Vivo and In Vitro Mechanisms of Equol Synthesis and Key Influencing Factors: A Critical Review.Nutrients · 2025Review
- Pharmacokinetic and pharmacodynamic studies of injectable nocathiacin as a novel antibacterial agent.npj antimicrobials and resistance · 2025Article
- Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy.Journal of cancer research and clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic potential of (S)-Equol across various health domains, including mental health and oncology has been identified and studied enormously. However, the pharmacokinetic study on the enantiopure (S)-Equol in male and female rats under graded doses remain untouched, and the study concentrates on the same. Male and female CD(SD)IGS rats were grouped into 8 groups and some groups were administered with 20, 60 and 160 mg/kg body weight, orally and other administered with intravenous bolus injection at 10 mg/kg body weight of (S)-Equol. The plasma (S)-Equol concentrations were estimated by LC-MS/MS and the pharmacokinetic parameters determined from the concentration time data by non-compartmental PK analysis. The observed (S)-Equol C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.